| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 215 | 2023 | 5709 | 4.450 |
Why?
|
| Skin Neoplasms | 203 | 2023 | 5821 | 4.230 |
Why?
|
| Dysplastic Nevus Syndrome | 18 | 2014 | 61 | 1.280 |
Why?
|
| Nevus, Pigmented | 26 | 2017 | 222 | 1.150 |
Why?
|
| Sentinel Lymph Node Biopsy | 17 | 2020 | 732 | 1.080 |
Why?
|
| Nevus | 14 | 2016 | 205 | 1.050 |
Why?
|
| Neoplasm Staging | 50 | 2016 | 11121 | 0.970 |
Why?
|
| Dermatology | 14 | 2019 | 918 | 0.640 |
Why?
|
| Lentigo | 10 | 2004 | 37 | 0.600 |
Why?
|
| Lymph Nodes | 14 | 2015 | 3466 | 0.550 |
Why?
|
| Sunlight | 10 | 1998 | 337 | 0.530 |
Why?
|
| Outpatient Clinics, Hospital | 3 | 2019 | 395 | 0.520 |
Why?
|
| Skin Diseases | 9 | 2017 | 1094 | 0.490 |
Why?
|
| Biopsy | 25 | 2020 | 6766 | 0.430 |
Why?
|
| Pathology, Clinical | 3 | 2012 | 376 | 0.420 |
Why?
|
| Lymphatic Metastasis | 31 | 2016 | 2915 | 0.400 |
Why?
|
| Neoplasms, Multiple Primary | 10 | 2014 | 592 | 0.360 |
Why?
|
| Pigmentation Disorders | 10 | 1993 | 105 | 0.360 |
Why?
|
| Carcinoma, Merkel Cell | 4 | 2016 | 328 | 0.340 |
Why?
|
| Facial Dermatoses | 2 | 2004 | 86 | 0.340 |
Why?
|
| Melanocytes | 18 | 2014 | 509 | 0.330 |
Why?
|
| Pregnancy Complications, Neoplastic | 4 | 1999 | 258 | 0.320 |
Why?
|
| Ultraviolet Rays | 5 | 1998 | 1080 | 0.310 |
Why?
|
| Prognosis | 67 | 2023 | 29625 | 0.300 |
Why?
|
| Interferon-alpha | 5 | 2004 | 921 | 0.280 |
Why?
|
| Facial Neoplasms | 4 | 2004 | 125 | 0.260 |
Why?
|
| Precancerous Conditions | 4 | 2004 | 980 | 0.240 |
Why?
|
| Humans | 261 | 2023 | 761504 | 0.230 |
Why?
|
| Lymph Node Excision | 12 | 2015 | 1271 | 0.220 |
Why?
|
| Genes, p16 | 3 | 2010 | 160 | 0.200 |
Why?
|
| Neoplasms, Second Primary | 4 | 2004 | 1052 | 0.180 |
Why?
|
| Skin Pigmentation | 6 | 1993 | 277 | 0.180 |
Why?
|
| Neoplasms, Unknown Primary | 2 | 2016 | 101 | 0.180 |
Why?
|
| Radiation Protection | 2 | 1998 | 424 | 0.180 |
Why?
|
| Middle Aged | 117 | 2018 | 220895 | 0.180 |
Why?
|
| Adult | 123 | 2017 | 221177 | 0.170 |
Why?
|
| Health Care Costs | 3 | 2017 | 3242 | 0.170 |
Why?
|
| Female | 152 | 2018 | 392644 | 0.170 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2011 | 4026 | 0.170 |
Why?
|
| Rosacea | 2 | 1992 | 59 | 0.170 |
Why?
|
| Consent Forms | 1 | 2019 | 55 | 0.160 |
Why?
|
| Lipomatosis, Multiple Symmetrical | 1 | 1998 | 8 | 0.160 |
Why?
|
| Cost of Illness | 3 | 2017 | 1936 | 0.160 |
Why?
|
| Sunscreening Agents | 3 | 1998 | 139 | 0.160 |
Why?
|
| Neoplasm Invasiveness | 15 | 2014 | 3595 | 0.160 |
Why?
|
| Skin | 20 | 1998 | 4484 | 0.160 |
Why?
|
| Keratosis | 4 | 1995 | 79 | 0.160 |
Why?
|
| Male | 140 | 2018 | 360804 | 0.150 |
Why?
|
| Survival Rate | 16 | 2018 | 12725 | 0.150 |
Why?
|
| Neoplasms, Radiation-Induced | 4 | 1987 | 549 | 0.150 |
Why?
|
| Survival Analysis | 10 | 2014 | 10090 | 0.150 |
Why?
|
| Polyps | 2 | 1992 | 200 | 0.140 |
Why?
|
| Skin Aging | 2 | 1996 | 141 | 0.140 |
Why?
|
| Aged | 80 | 2018 | 169289 | 0.140 |
Why?
|
| Cholecystitis | 1 | 1997 | 180 | 0.130 |
Why?
|
| Arm | 5 | 2004 | 589 | 0.130 |
Why?
|
| Bowen's Disease | 1 | 1995 | 13 | 0.120 |
Why?
|
| Neoplasm Regression, Spontaneous | 2 | 1993 | 46 | 0.120 |
Why?
|
| Gallbladder Neoplasms | 1 | 1997 | 189 | 0.120 |
Why?
|
| Doxepin | 1 | 1994 | 16 | 0.120 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2002 | 1374 | 0.120 |
Why?
|
| Laser Therapy | 2 | 1999 | 1092 | 0.120 |
Why?
|
| Risk Factors | 30 | 2016 | 74206 | 0.110 |
Why?
|
| False Negative Reactions | 3 | 2012 | 573 | 0.110 |
Why?
|
| Clobetasol | 1 | 1994 | 33 | 0.110 |
Why?
|
| Aged, 80 and over | 30 | 2016 | 58976 | 0.110 |
Why?
|
| Neoadjuvant Therapy | 1 | 2005 | 2827 | 0.110 |
Why?
|
| Lymphedema | 1 | 2000 | 525 | 0.110 |
Why?
|
| Microscopy | 3 | 1994 | 903 | 0.110 |
Why?
|
| Arthritis, Psoriatic | 1 | 2016 | 219 | 0.110 |
Why?
|
| Adolescent | 42 | 2018 | 88319 | 0.100 |
Why?
|
| Nonprescription Drugs | 1 | 1994 | 118 | 0.100 |
Why?
|
| Informed Consent | 1 | 2019 | 1008 | 0.100 |
Why?
|
| Antineoplastic Agents | 9 | 2016 | 13639 | 0.100 |
Why?
|
| Cyclin-Dependent Kinases | 4 | 2004 | 655 | 0.100 |
Why?
|
| Chemotherapy, Adjuvant | 7 | 2016 | 3514 | 0.100 |
Why?
|
| Age Factors | 16 | 2018 | 18395 | 0.100 |
Why?
|
| Hospitals, General | 2 | 2013 | 798 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 15 | 2014 | 9280 | 0.100 |
Why?
|
| Nevus, Epithelioid and Spindle Cell | 2 | 2011 | 70 | 0.100 |
Why?
|
| Massachusetts | 6 | 2015 | 8830 | 0.100 |
Why?
|
| Ear Neoplasms | 1 | 1992 | 118 | 0.090 |
Why?
|
| Self-Examination | 4 | 2015 | 71 | 0.090 |
Why?
|
| Photography | 5 | 2001 | 532 | 0.090 |
Why?
|
| Ear Canal | 1 | 1992 | 147 | 0.090 |
Why?
|
| History, 21st Century | 2 | 2010 | 1567 | 0.090 |
Why?
|
| Pruritus | 1 | 1994 | 380 | 0.090 |
Why?
|
| Time Factors | 26 | 2012 | 39967 | 0.090 |
Why?
|
| Genital Diseases, Female | 1 | 1992 | 192 | 0.090 |
Why?
|
| Algorithms | 6 | 2017 | 14031 | 0.090 |
Why?
|
| Manuals as Topic | 1 | 2010 | 99 | 0.090 |
Why?
|
| Cancer Vaccines | 3 | 2005 | 1051 | 0.090 |
Why?
|
| Diagnosis, Differential | 14 | 2012 | 12974 | 0.090 |
Why?
|
| Metronidazole | 2 | 1992 | 232 | 0.090 |
Why?
|
| Leg Dermatoses | 1 | 1989 | 20 | 0.090 |
Why?
|
| Life Expectancy | 1 | 2017 | 1242 | 0.090 |
Why?
|
| Penile Diseases | 1 | 1990 | 45 | 0.090 |
Why?
|
| Mycobacterium Infections | 2 | 1989 | 122 | 0.080 |
Why?
|
| Vulvar Diseases | 1 | 1990 | 64 | 0.080 |
Why?
|
| Back | 2 | 1988 | 64 | 0.080 |
Why?
|
| Retrospective Studies | 29 | 2020 | 80636 | 0.080 |
Why?
|
| Incidence | 10 | 2017 | 21353 | 0.080 |
Why?
|
| United States | 22 | 2017 | 72334 | 0.080 |
Why?
|
| Child | 28 | 2018 | 80153 | 0.080 |
Why?
|
| SEER Program | 3 | 2013 | 1450 | 0.080 |
Why?
|
| History, 20th Century | 2 | 2010 | 2767 | 0.080 |
Why?
|
| Receptors, Progesterone | 1 | 1994 | 1129 | 0.080 |
Why?
|
| Protective Devices | 1 | 1989 | 72 | 0.080 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 2759 | 0.080 |
Why?
|
| Risk Assessment | 11 | 2023 | 23995 | 0.080 |
Why?
|
| BCG Vaccine | 3 | 1989 | 369 | 0.080 |
Why?
|
| Mass Screening | 6 | 2003 | 5428 | 0.080 |
Why?
|
| Teaching | 1 | 1996 | 1170 | 0.080 |
Why?
|
| Triage | 2 | 2011 | 986 | 0.080 |
Why?
|
| Boston | 7 | 2012 | 9326 | 0.080 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 2 | 1990 | 94 | 0.080 |
Why?
|
| Secondary Prevention | 2 | 2004 | 1475 | 0.080 |
Why?
|
| Granuloma | 2 | 1989 | 328 | 0.080 |
Why?
|
| Head Protective Devices | 1 | 1989 | 118 | 0.070 |
Why?
|
| Follow-Up Studies | 21 | 2015 | 39106 | 0.070 |
Why?
|
| Epidemics | 1 | 2013 | 512 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2004 | 4511 | 0.070 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 3 | 2000 | 698 | 0.070 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2012 | 746 | 0.070 |
Why?
|
| Dermatitis, Atopic | 1 | 1994 | 731 | 0.070 |
Why?
|
| Carotenoids | 5 | 1990 | 621 | 0.070 |
Why?
|
| Scalp | 2 | 1992 | 389 | 0.070 |
Why?
|
| Sex Distribution | 4 | 2007 | 2281 | 0.070 |
Why?
|
| Neoplasm Proteins | 3 | 2005 | 3617 | 0.070 |
Why?
|
| Neoplasm Metastasis | 15 | 2009 | 4915 | 0.070 |
Why?
|
| Age Distribution | 4 | 2007 | 2880 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 2 | 2016 | 7390 | 0.060 |
Why?
|
| Cicatrix | 2 | 1990 | 798 | 0.060 |
Why?
|
| Image Processing, Computer-Assisted | 6 | 2001 | 9000 | 0.060 |
Why?
|
| Child, Preschool | 14 | 2018 | 42230 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2006 | 4016 | 0.060 |
Why?
|
| Receptors, Estrogen | 1 | 1994 | 2208 | 0.060 |
Why?
|
| Choroid Neoplasms | 2 | 1986 | 177 | 0.060 |
Why?
|
| Guideline Adherence | 1 | 2016 | 2220 | 0.060 |
Why?
|
| Hutchinson's Melanotic Freckle | 3 | 2011 | 25 | 0.060 |
Why?
|
| Health Education | 3 | 2015 | 1052 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 4 | 2005 | 2825 | 0.060 |
Why?
|
| Tumor Burden | 4 | 2014 | 1893 | 0.060 |
Why?
|
| Neck | 2 | 1988 | 734 | 0.060 |
Why?
|
| Germ-Line Mutation | 5 | 2010 | 1858 | 0.060 |
Why?
|
| Family Practice | 2 | 1998 | 512 | 0.060 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 1998 | 891 | 0.060 |
Why?
|
| Hypopigmentation | 2 | 2002 | 43 | 0.060 |
Why?
|
| Models, Genetic | 2 | 2010 | 3442 | 0.060 |
Why?
|
| Amines | 2 | 2000 | 281 | 0.060 |
Why?
|
| Research Design | 2 | 1999 | 6180 | 0.050 |
Why?
|
| Siblings | 2 | 2006 | 825 | 0.050 |
Why?
|
| Rectal Neoplasms | 1 | 1992 | 1157 | 0.050 |
Why?
|
| Membrane Glycoproteins | 2 | 2005 | 3702 | 0.050 |
Why?
|
| Recombinant Proteins | 5 | 2004 | 6534 | 0.050 |
Why?
|
| Pedigree | 4 | 2010 | 4542 | 0.050 |
Why?
|
| Registries | 2 | 2013 | 8224 | 0.050 |
Why?
|
| Dermatomycoses | 3 | 1985 | 48 | 0.050 |
Why?
|
| Immunotherapy | 6 | 2005 | 4652 | 0.050 |
Why?
|
| Keratosis, Seborrheic | 1 | 2002 | 27 | 0.050 |
Why?
|
| Sex Factors | 8 | 2013 | 10552 | 0.050 |
Why?
|
| Office Visits | 1 | 2006 | 595 | 0.050 |
Why?
|
| Melphalan | 1 | 1984 | 420 | 0.050 |
Why?
|
| Point Mutation | 3 | 1998 | 1595 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1999 | 10209 | 0.050 |
Why?
|
| Spectrophotometry | 2 | 2001 | 309 | 0.050 |
Why?
|
| Mohs Surgery | 1 | 2004 | 222 | 0.050 |
Why?
|
| Pregnancy | 9 | 1999 | 29874 | 0.050 |
Why?
|
| Patient Satisfaction | 2 | 2006 | 3461 | 0.050 |
Why?
|
| Interferons | 1 | 2005 | 706 | 0.050 |
Why?
|
| Porphyrias | 1 | 1981 | 57 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 2 | 2013 | 5492 | 0.050 |
Why?
|
| Monophenol Monooxygenase | 1 | 2001 | 72 | 0.050 |
Why?
|
| Risk | 10 | 2005 | 9610 | 0.050 |
Why?
|
| Ectropion | 1 | 1981 | 27 | 0.050 |
Why?
|
| Expert Systems | 1 | 2001 | 79 | 0.050 |
Why?
|
| Psoriasis | 2 | 2006 | 950 | 0.050 |
Why?
|
| Vitamin E | 3 | 1990 | 872 | 0.050 |
Why?
|
| Infant | 9 | 2017 | 36192 | 0.050 |
Why?
|
| Lacrimal Duct Obstruction | 1 | 1981 | 53 | 0.050 |
Why?
|
| Patient Education as Topic | 3 | 2002 | 2319 | 0.040 |
Why?
|
| Databases, Factual | 5 | 2016 | 7967 | 0.040 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 3201 | 0.040 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 1983 | 246 | 0.040 |
Why?
|
| Societies, Medical | 2 | 2010 | 3905 | 0.040 |
Why?
|
| Gonadal Steroid Hormones | 2 | 1999 | 702 | 0.040 |
Why?
|
| Military Personnel | 1 | 1989 | 1246 | 0.040 |
Why?
|
| Erythema | 3 | 2006 | 262 | 0.040 |
Why?
|
| Emigration and Immigration | 2 | 1997 | 397 | 0.040 |
Why?
|
| Technetium | 1 | 1979 | 317 | 0.040 |
Why?
|
| Forecasting | 2 | 2002 | 2928 | 0.040 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2000 | 140 | 0.040 |
Why?
|
| Disease-Free Survival | 4 | 2014 | 6814 | 0.040 |
Why?
|
| Biopsy, Needle | 4 | 2007 | 1626 | 0.040 |
Why?
|
| Homeopathy | 1 | 1999 | 30 | 0.040 |
Why?
|
| Carcinoma, Basal Cell | 4 | 1995 | 560 | 0.040 |
Why?
|
| Patient Selection | 2 | 2010 | 4244 | 0.040 |
Why?
|
| Sulfur | 1 | 1979 | 162 | 0.040 |
Why?
|
| Skin Transplantation | 1 | 2004 | 1083 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2017 | 5336 | 0.040 |
Why?
|
| Glucosamine | 1 | 1979 | 128 | 0.040 |
Why?
|
| Clinical Trials as Topic | 4 | 2010 | 8002 | 0.040 |
Why?
|
| Acetates | 1 | 2000 | 321 | 0.040 |
Why?
|
| Levodopa | 2 | 1983 | 221 | 0.040 |
Why?
|
| Aspergillosis | 1 | 1980 | 242 | 0.040 |
Why?
|
| Sunburn | 3 | 1991 | 156 | 0.040 |
Why?
|
| Evidence-Based Medicine | 3 | 2011 | 3688 | 0.040 |
Why?
|
| Vitamin D | 1 | 1992 | 3303 | 0.040 |
Why?
|
| Young Adult | 8 | 2018 | 59243 | 0.040 |
Why?
|
| Estrogens | 1 | 1985 | 1522 | 0.040 |
Why?
|
| Program Evaluation | 2 | 2019 | 2495 | 0.040 |
Why?
|
| Hyperplasia | 4 | 1994 | 1152 | 0.040 |
Why?
|
| Hyperhidrosis | 1 | 1978 | 34 | 0.040 |
Why?
|
| Cheek | 1 | 1998 | 65 | 0.040 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2001 | 946 | 0.040 |
Why?
|
| Spleen | 2 | 1984 | 2295 | 0.040 |
Why?
|
| Vitiligo | 3 | 1986 | 97 | 0.040 |
Why?
|
| Epidemiologic Methods | 2 | 1997 | 1336 | 0.040 |
Why?
|
| Anti-Anxiety Agents | 1 | 2000 | 397 | 0.040 |
Why?
|
| Probability | 2 | 2005 | 2477 | 0.040 |
Why?
|
| Immunohistochemistry | 7 | 2005 | 11076 | 0.040 |
Why?
|
| Cohort Studies | 8 | 2018 | 41487 | 0.040 |
Why?
|
| Health Services Accessibility | 3 | 2011 | 5440 | 0.040 |
Why?
|
| Referral and Consultation | 3 | 2015 | 3600 | 0.040 |
Why?
|
| Foot | 3 | 1997 | 575 | 0.040 |
Why?
|
| Radiography, Thoracic | 1 | 2004 | 1302 | 0.040 |
Why?
|
| Dermoscopy | 1 | 2017 | 66 | 0.040 |
Why?
|
| Censuses | 1 | 1998 | 202 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2005 | 4111 | 0.030 |
Why?
|
| Hydrocortisone | 2 | 1977 | 1819 | 0.030 |
Why?
|
| Metals | 1 | 1981 | 719 | 0.030 |
Why?
|
| Monoamine Oxidase | 2 | 1967 | 181 | 0.030 |
Why?
|
| Antimanic Agents | 1 | 2000 | 520 | 0.030 |
Why?
|
| Dendritic Cells | 2 | 2005 | 2747 | 0.030 |
Why?
|
| Vaccines | 1 | 2005 | 844 | 0.030 |
Why?
|
| Methotrexate | 1 | 1983 | 1719 | 0.030 |
Why?
|
| World Health Organization | 1 | 2002 | 1322 | 0.030 |
Why?
|
| Endometriosis | 2 | 1997 | 870 | 0.030 |
Why?
|
| Lung Neoplasms | 3 | 2005 | 13380 | 0.030 |
Why?
|
| Medical Records | 1 | 2002 | 1408 | 0.030 |
Why?
|
| Hospital Charges | 1 | 1998 | 350 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase 4 | 4 | 2004 | 561 | 0.030 |
Why?
|
| Lymphokines | 1 | 1979 | 927 | 0.030 |
Why?
|
| Luminescent Measurements | 2 | 1994 | 342 | 0.030 |
Why?
|
| Catecholamines | 1 | 1977 | 386 | 0.030 |
Why?
|
| Observer Variation | 2 | 1993 | 2606 | 0.030 |
Why?
|
| Uveitis | 2 | 1986 | 395 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2001 | 1971 | 0.030 |
Why?
|
| Lung | 1 | 1994 | 10000 | 0.030 |
Why?
|
| Models, Biological | 6 | 2009 | 9469 | 0.030 |
Why?
|
| Pharmaceutical Vehicles | 1 | 1994 | 57 | 0.030 |
Why?
|
| Prevalence | 3 | 2017 | 15732 | 0.030 |
Why?
|
| Infant, Premature, Diseases | 1 | 1980 | 710 | 0.030 |
Why?
|
| Hepatomegaly | 1 | 1974 | 84 | 0.030 |
Why?
|
| Hair Color | 2 | 1992 | 131 | 0.030 |
Why?
|
| gp100 Melanoma Antigen | 2 | 2005 | 38 | 0.030 |
Why?
|
| Adrenal Glands | 1 | 1977 | 552 | 0.030 |
Why?
|
| Case-Control Studies | 7 | 2007 | 22176 | 0.030 |
Why?
|
| Dermatologic Agents | 1 | 1978 | 313 | 0.030 |
Why?
|
| Hand | 3 | 1997 | 902 | 0.030 |
Why?
|
| Models, Economic | 1 | 1998 | 716 | 0.030 |
Why?
|
| Splenomegaly | 1 | 1974 | 189 | 0.030 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2000 | 1141 | 0.030 |
Why?
|
| Risk Adjustment | 1 | 2017 | 600 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2001 | 4575 | 0.030 |
Why?
|
| Glucose Tolerance Test | 1 | 1977 | 1178 | 0.030 |
Why?
|
| Skin Diseases, Infectious | 2 | 1985 | 76 | 0.030 |
Why?
|
| General Practitioners | 1 | 2015 | 101 | 0.030 |
Why?
|
| Curriculum | 2 | 1998 | 3743 | 0.030 |
Why?
|
| Alopecia | 1 | 1978 | 412 | 0.030 |
Why?
|
| Lymphocytes | 2 | 1998 | 2612 | 0.030 |
Why?
|
| Bone Neoplasms | 5 | 2005 | 2529 | 0.030 |
Why?
|
| Connecticut | 1 | 2013 | 364 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2005 | 5112 | 0.030 |
Why?
|
| Physicians, Family | 1 | 2015 | 350 | 0.030 |
Why?
|
| Prospective Studies | 14 | 2005 | 54425 | 0.030 |
Why?
|
| Skin Ulcer | 3 | 2000 | 130 | 0.030 |
Why?
|
| Predictive Value of Tests | 4 | 2014 | 15266 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 1998 | 1668 | 0.030 |
Why?
|
| beta Carotene | 4 | 1990 | 523 | 0.030 |
Why?
|
| Administration, Cutaneous | 1 | 1994 | 713 | 0.030 |
Why?
|
| Reproducibility of Results | 4 | 2012 | 20098 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2002 | 2690 | 0.020 |
Why?
|
| Eczema | 1 | 1994 | 246 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1996 | 1062 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2005 | 4580 | 0.020 |
Why?
|
| Employment | 1 | 1998 | 1118 | 0.020 |
Why?
|
| Acromegaly | 1 | 1974 | 310 | 0.020 |
Why?
|
| Neoplasms | 3 | 2009 | 22170 | 0.020 |
Why?
|
| Vasopressins | 1 | 1972 | 351 | 0.020 |
Why?
|
| Aminoquinolines | 1 | 2011 | 107 | 0.020 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 1998 | 1092 | 0.020 |
Why?
|
| Genes, p53 | 1 | 1993 | 712 | 0.020 |
Why?
|
| Actuarial Analysis | 3 | 1986 | 372 | 0.020 |
Why?
|
| Nail Diseases | 1 | 2011 | 55 | 0.020 |
Why?
|
| Statistics as Topic | 7 | 1997 | 2358 | 0.020 |
Why?
|
| RNA, Messenger | 3 | 2001 | 12795 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2016 | 1784 | 0.020 |
Why?
|
| Diet | 4 | 1992 | 8075 | 0.020 |
Why?
|
| Cryotherapy | 1 | 2011 | 159 | 0.020 |
Why?
|
| Carcinoma in Situ | 1 | 1996 | 791 | 0.020 |
Why?
|
| Sleep Stages | 1 | 1994 | 694 | 0.020 |
Why?
|
| Sensitivity and Specificity | 4 | 2015 | 14666 | 0.020 |
Why?
|
| Phenethylamines | 2 | 1967 | 95 | 0.020 |
Why?
|
| Phenotype | 3 | 2005 | 16591 | 0.020 |
Why?
|
| Public Health | 1 | 2023 | 2669 | 0.020 |
Why?
|
| Food Analysis | 1 | 1990 | 103 | 0.020 |
Why?
|
| Japan | 2 | 1996 | 1378 | 0.020 |
Why?
|
| Medicare | 2 | 2017 | 6770 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2015 | 823 | 0.020 |
Why?
|
| Combined Modality Therapy | 6 | 1997 | 8529 | 0.020 |
Why?
|
| Pigmentation | 3 | 1985 | 144 | 0.020 |
Why?
|
| Pituitary-Adrenal System | 1 | 1972 | 552 | 0.020 |
Why?
|
| Endometrium | 1 | 1992 | 403 | 0.020 |
Why?
|
| Methods | 3 | 1982 | 1067 | 0.020 |
Why?
|
| Income | 1 | 1998 | 1877 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 1994 | 1745 | 0.020 |
Why?
|
| Telemedicine | 1 | 2006 | 3051 | 0.020 |
Why?
|
| Infant, Newborn | 5 | 2017 | 26198 | 0.020 |
Why?
|
| Hospitals, Urban | 1 | 2011 | 500 | 0.020 |
Why?
|
| Random Allocation | 3 | 1991 | 2395 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 1993 | 1386 | 0.020 |
Why?
|
| Drug Costs | 1 | 2017 | 1183 | 0.020 |
Why?
|
| Physical Examination | 2 | 1986 | 1255 | 0.020 |
Why?
|
| Eye Neoplasms | 1 | 1990 | 307 | 0.020 |
Why?
|
| Reference Standards | 1 | 2012 | 1003 | 0.020 |
Why?
|
| Mathematics | 1 | 2009 | 707 | 0.020 |
Why?
|
| Asymptomatic Diseases | 1 | 2011 | 588 | 0.020 |
Why?
|
| Immune Tolerance | 3 | 1987 | 2303 | 0.020 |
Why?
|
| Anus Neoplasms | 1 | 1992 | 329 | 0.020 |
Why?
|
| Physicians, Primary Care | 1 | 2015 | 623 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2017 | 15842 | 0.020 |
Why?
|
| Macrophages | 3 | 1998 | 5769 | 0.020 |
Why?
|
| Penetrance | 1 | 2010 | 383 | 0.020 |
Why?
|
| Retinoblastoma | 1 | 1990 | 317 | 0.020 |
Why?
|
| Butylamines | 1 | 1967 | 9 | 0.020 |
Why?
|
| Ethylamines | 1 | 1967 | 17 | 0.020 |
Why?
|
| Radionuclide Imaging | 3 | 1999 | 1972 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2010 | 15631 | 0.020 |
Why?
|
| Population Surveillance | 1 | 1998 | 2598 | 0.020 |
Why?
|
| Health Surveys | 1 | 2017 | 4061 | 0.020 |
Why?
|
| Xeroderma Pigmentosum | 1 | 1987 | 31 | 0.020 |
Why?
|
| Double-Blind Method | 2 | 1994 | 12341 | 0.020 |
Why?
|
| Abortion, Spontaneous | 1 | 1992 | 533 | 0.020 |
Why?
|
| Dacarbazine | 1 | 1990 | 559 | 0.020 |
Why?
|
| Logistic Models | 2 | 2016 | 13255 | 0.020 |
Why?
|
| Hysterectomy | 1 | 1992 | 857 | 0.020 |
Why?
|
| Recurrence | 3 | 1998 | 8465 | 0.020 |
Why?
|
| Propylamines | 1 | 1967 | 161 | 0.020 |
Why?
|
| Eye Diseases | 2 | 1986 | 653 | 0.020 |
Why?
|
| Biological Specimen Banks | 1 | 2012 | 783 | 0.020 |
Why?
|
| Antibodies, Neoplasm | 2 | 1999 | 281 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2020 | 3205 | 0.020 |
Why?
|
| Epidermis | 2 | 1993 | 528 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 5 | 2000 | 2895 | 0.020 |
Why?
|
| Acute Disease | 1 | 1997 | 7237 | 0.020 |
Why?
|
| Terminal Care | 1 | 1998 | 1760 | 0.020 |
Why?
|
| Syndrome | 2 | 1985 | 3267 | 0.020 |
Why?
|
| Guinea Pigs | 3 | 1986 | 1310 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 1987 | 641 | 0.020 |
Why?
|
| PUVA Therapy | 1 | 1986 | 101 | 0.020 |
Why?
|
| Intraoperative Care | 2 | 2000 | 767 | 0.020 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 1987 | 190 | 0.020 |
Why?
|
| Soft Tissue Neoplasms | 1 | 1994 | 1159 | 0.020 |
Why?
|
| Intestinal Neoplasms | 3 | 1983 | 312 | 0.020 |
Why?
|
| Dicarboxylic Acids | 1 | 1985 | 77 | 0.020 |
Why?
|
| HLA-A Antigens | 1 | 2005 | 223 | 0.020 |
Why?
|
| HLA-A2 Antigen | 1 | 2005 | 211 | 0.020 |
Why?
|
| Multivariate Analysis | 4 | 2003 | 12059 | 0.020 |
Why?
|
| Breast Neoplasms | 2 | 2009 | 21012 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2012 | 1265 | 0.010 |
Why?
|
| Insurance, Health | 1 | 2017 | 2498 | 0.010 |
Why?
|
| Ontario | 1 | 2005 | 398 | 0.010 |
Why?
|
| Vaccination | 1 | 1997 | 3384 | 0.010 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 2 | 1999 | 63 | 0.010 |
Why?
|
| Financing, Personal | 1 | 2006 | 309 | 0.010 |
Why?
|
| HLA Antigens | 2 | 1982 | 1328 | 0.010 |
Why?
|
| Flow Cytometry | 3 | 2005 | 5869 | 0.010 |
Why?
|
| Medicaid | 1 | 2017 | 2818 | 0.010 |
Why?
|
| Reoperation | 1 | 2014 | 4303 | 0.010 |
Why?
|
| Actins | 1 | 1991 | 2050 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2001 | 7856 | 0.010 |
Why?
|
| Treatment Outcome | 5 | 2012 | 64680 | 0.010 |
Why?
|
| Meta-Analysis as Topic | 1 | 1988 | 1380 | 0.010 |
Why?
|
| Patient-Centered Care | 1 | 2013 | 1421 | 0.010 |
Why?
|
| Proportional Hazards Models | 3 | 2004 | 12463 | 0.010 |
Why?
|
| Foot Diseases | 2 | 1982 | 147 | 0.010 |
Why?
|
| Beta-Globulins | 1 | 1982 | 27 | 0.010 |
Why?
|
| Educational Status | 1 | 1991 | 2522 | 0.010 |
Why?
|
| Dermatitis, Exfoliative | 1 | 1983 | 27 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 1996 | 4936 | 0.010 |
Why?
|
| Sarcoma | 1 | 1994 | 1801 | 0.010 |
Why?
|
| Case Management | 1 | 2005 | 272 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2005 | 883 | 0.010 |
Why?
|
| Breast | 1 | 1992 | 1967 | 0.010 |
Why?
|
| Bipolar Disorder | 1 | 2000 | 5092 | 0.010 |
Why?
|
| Liver Neoplasms | 3 | 2005 | 4320 | 0.010 |
Why?
|
| Pyrimidine Dimers | 1 | 1982 | 18 | 0.010 |
Why?
|
| Nutrition Surveys | 1 | 1990 | 1733 | 0.010 |
Why?
|
| Regression Analysis | 3 | 1992 | 6343 | 0.010 |
Why?
|
| Australia | 1 | 1986 | 1250 | 0.010 |
Why?
|
| MART-1 Antigen | 1 | 2002 | 65 | 0.010 |
Why?
|
| Patient Care Team | 1 | 2013 | 2521 | 0.010 |
Why?
|
| Drug Therapy | 1 | 1985 | 503 | 0.010 |
Why?
|
| Mortality | 1 | 2013 | 2901 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 6484 | 0.010 |
Why?
|
| Social Class | 1 | 1991 | 2004 | 0.010 |
Why?
|
| Argyria | 1 | 1981 | 2 | 0.010 |
Why?
|
| Genetic Engineering | 2 | 1998 | 933 | 0.010 |
Why?
|
| beta 2-Microglobulin | 1 | 1982 | 329 | 0.010 |
Why?
|
| Demography | 1 | 2006 | 1648 | 0.010 |
Why?
|
| Phenothiazines | 1 | 1981 | 61 | 0.010 |
Why?
|
| Bismuth | 1 | 1981 | 29 | 0.010 |
Why?
|
| Smoking | 3 | 1990 | 9053 | 0.010 |
Why?
|
| Proteins | 1 | 1996 | 6032 | 0.010 |
Why?
|
| Clofazimine | 1 | 1981 | 41 | 0.010 |
Why?
|
| Early Diagnosis | 1 | 2006 | 1186 | 0.010 |
Why?
|
| Tetracyclines | 1 | 1981 | 64 | 0.010 |
Why?
|
| Disease Progression | 2 | 2015 | 13506 | 0.010 |
Why?
|
| Community-Institutional Relations | 1 | 2002 | 206 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2005 | 10766 | 0.010 |
Why?
|
| Photosensitivity Disorders | 1 | 1981 | 80 | 0.010 |
Why?
|
| Sarcoma, Kaposi | 1 | 1984 | 374 | 0.010 |
Why?
|
| Consensus | 1 | 2010 | 3123 | 0.010 |
Why?
|
| Geography | 1 | 1982 | 656 | 0.010 |
Why?
|
| Genetic Counseling | 1 | 2004 | 627 | 0.010 |
Why?
|
| Carcinogens | 1 | 1982 | 452 | 0.010 |
Why?
|
| Cell Separation | 1 | 2005 | 1720 | 0.010 |
Why?
|
| Abdomen | 1 | 2006 | 1128 | 0.010 |
Why?
|
| TRPM Cation Channels | 1 | 2001 | 139 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2005 | 2850 | 0.010 |
Why?
|
| Colloids | 1 | 1979 | 123 | 0.010 |
Why?
|
| Remission Induction | 1 | 2005 | 2396 | 0.010 |
Why?
|
| Drug Eruptions | 1 | 1983 | 335 | 0.010 |
Why?
|
| Amiodarone | 1 | 1981 | 217 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 2 | 1998 | 6132 | 0.010 |
Why?
|
| Microchemistry | 1 | 1979 | 54 | 0.010 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1981 | 618 | 0.010 |
Why?
|
| Iritis | 1 | 1978 | 15 | 0.010 |
Why?
|
| Hodgkin Disease | 1 | 1987 | 1378 | 0.010 |
Why?
|
| Vitamin A | 1 | 1982 | 613 | 0.010 |
Why?
|
| Bandages | 1 | 1980 | 269 | 0.010 |
Why?
|
| Leg | 1 | 1984 | 1088 | 0.010 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2000 | 411 | 0.010 |
Why?
|
| Porphyrins | 1 | 1981 | 352 | 0.010 |
Why?
|
| Contraceptives, Oral | 1 | 1981 | 554 | 0.010 |
Why?
|
| Miliaria | 1 | 1978 | 6 | 0.010 |
Why?
|
| Vascular Diseases | 1 | 1987 | 1161 | 0.010 |
Why?
|
| Mercury | 1 | 1981 | 290 | 0.010 |
Why?
|
| Alcohol Drinking | 2 | 1990 | 4028 | 0.010 |
Why?
|
| Lead Poisoning | 1 | 1981 | 322 | 0.010 |
Why?
|
| Quality of Health Care | 1 | 2013 | 4330 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 3810 | 0.010 |
Why?
|
| Occlusive Dressings | 1 | 1978 | 52 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 1985 | 1787 | 0.010 |
Why?
|
| Reference Values | 1 | 2005 | 4920 | 0.010 |
Why?
|
| Aging | 2 | 1991 | 8708 | 0.010 |
Why?
|
| Iron | 2 | 1990 | 1793 | 0.010 |
Why?
|
| Adenoviridae | 1 | 2002 | 1084 | 0.010 |
Why?
|
| Age of Onset | 2 | 1996 | 3305 | 0.010 |
Why?
|
| Feeding Behavior | 1 | 1990 | 3188 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1998 | 329 | 0.010 |
Why?
|
| Arsenic | 1 | 1981 | 362 | 0.010 |
Why?
|
| Plastics | 1 | 1978 | 117 | 0.010 |
Why?
|
| Aluminum | 1 | 1978 | 152 | 0.010 |
Why?
|
| Hypersensitivity, Delayed | 1 | 1998 | 490 | 0.010 |
Why?
|
| Gold | 1 | 1981 | 482 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 1993 | 8547 | 0.010 |
Why?
|
| Color | 2 | 1993 | 299 | 0.010 |
Why?
|
| Abnormalities, Multiple | 1 | 2005 | 1423 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2011 | 3530 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2005 | 3162 | 0.010 |
Why?
|
| Culture Media | 1 | 1979 | 897 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2001 | 1900 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 1994 | 9177 | 0.010 |
Why?
|
| Imidazoles | 1 | 1983 | 1180 | 0.010 |
Why?
|
| Tumor Suppressor Protein p14ARF | 1 | 1996 | 84 | 0.010 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2003 | 1192 | 0.010 |
Why?
|
| Animals | 7 | 1998 | 168459 | 0.010 |
Why?
|
| Codon | 1 | 1998 | 601 | 0.010 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1976 | 321 | 0.010 |
Why?
|
| Immunity, Cellular | 2 | 1986 | 1560 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 2001 | 908 | 0.010 |
Why?
|
| Primary Prevention | 1 | 1983 | 1186 | 0.010 |
Why?
|
| Chlorides | 1 | 1978 | 665 | 0.010 |
Why?
|
| Herpes Zoster | 2 | 1983 | 253 | 0.010 |
Why?
|
| Diploidy | 1 | 1994 | 132 | 0.010 |
Why?
|
| Salivary Gland Diseases | 1 | 1974 | 37 | 0.010 |
Why?
|
| Hemangioma | 2 | 1993 | 727 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 1996 | 535 | 0.010 |
Why?
|
| Antimalarials | 1 | 1981 | 907 | 0.010 |
Why?
|
| S100 Proteins | 1 | 1995 | 218 | 0.010 |
Why?
|
| Feces | 1 | 1981 | 1497 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 2002 | 1993 | 0.010 |
Why?
|
| Antioxidants | 1 | 1982 | 1668 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 1996 | 638 | 0.010 |
Why?
|
| Vimentin | 1 | 1995 | 255 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2010 | 17904 | 0.010 |
Why?
|
| Base Sequence | 2 | 1996 | 12441 | 0.010 |
Why?
|
| Gaucher Disease | 1 | 1974 | 110 | 0.010 |
Why?
|
| Skin Tests | 1 | 1976 | 637 | 0.010 |
Why?
|
| Eosinophils | 1 | 1998 | 950 | 0.010 |
Why?
|
| Cell Nucleus | 2 | 1994 | 2909 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 1996 | 750 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 1998 | 2115 | 0.010 |
Why?
|
| Mood Disorders | 1 | 2000 | 1127 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2001 | 2919 | 0.010 |
Why?
|
| Peptides | 1 | 2005 | 4358 | 0.010 |
Why?
|
| Computational Biology | 1 | 2005 | 3518 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2011 | 11528 | 0.010 |
Why?
|
| Pigments, Biological | 1 | 1993 | 52 | 0.010 |
Why?
|
| Salivary Glands | 1 | 1974 | 229 | 0.010 |
Why?
|
| ROC Curve | 1 | 2001 | 3579 | 0.010 |
Why?
|
| Cytological Techniques | 1 | 1994 | 218 | 0.010 |
Why?
|
| Liver Function Tests | 1 | 1974 | 523 | 0.010 |
Why?
|
| Treatment Failure | 1 | 1999 | 2645 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1993 | 767 | 0.010 |
Why?
|
| Bone Marrow Diseases | 1 | 1974 | 233 | 0.010 |
Why?
|
| Hyperpigmentation | 1 | 1994 | 117 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 1996 | 17635 | 0.010 |
Why?
|
| Piperazines | 1 | 1983 | 2523 | 0.010 |
Why?
|
| Diabetes Insipidus | 1 | 1972 | 144 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 1967 | 2496 | 0.010 |
Why?
|
| Sequence Deletion | 1 | 1996 | 1494 | 0.010 |
Why?
|
| DNA Primers | 1 | 1996 | 2819 | 0.010 |
Why?
|
| Attitude to Health | 1 | 2001 | 2025 | 0.010 |
Why?
|
| Conjunctival Neoplasms | 1 | 1992 | 77 | 0.010 |
Why?
|
| Exons | 1 | 1998 | 2391 | 0.010 |
Why?
|
| Microscopy, Phase-Contrast | 1 | 1991 | 110 | 0.010 |
Why?
|
| RNA Splicing | 1 | 1996 | 918 | 0.010 |
Why?
|
| Atlases as Topic | 1 | 1993 | 248 | 0.010 |
Why?
|
| Melanosis | 1 | 1992 | 93 | 0.010 |
Why?
|
| Odds Ratio | 2 | 1997 | 9646 | 0.010 |
Why?
|
| Aneuploidy | 1 | 1994 | 551 | 0.010 |
Why?
|
| Hemorrhage | 1 | 1983 | 3424 | 0.010 |
Why?
|
| Genotype | 1 | 2005 | 12990 | 0.010 |
Why?
|
| Culture Techniques | 1 | 1991 | 531 | 0.010 |
Why?
|
| Eye Enucleation | 1 | 1990 | 128 | 0.010 |
Why?
|
| Infertility, Female | 1 | 1997 | 760 | 0.010 |
Why?
|
| Rabbits | 2 | 1967 | 4772 | 0.010 |
Why?
|
| Brain Neoplasms | 2 | 2005 | 9031 | 0.010 |
Why?
|
| Extremities | 2 | 1986 | 867 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2001 | 5247 | 0.010 |
Why?
|
| Pituitary Gland | 1 | 1972 | 635 | 0.010 |
Why?
|
| Cell Division | 1 | 1997 | 4465 | 0.010 |
Why?
|
| Cell Nucleolus | 1 | 1990 | 156 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 1999 | 2651 | 0.010 |
Why?
|
| Neuroblastoma | 1 | 1998 | 1250 | 0.010 |
Why?
|
| Kinetics | 2 | 1967 | 6374 | 0.010 |
Why?
|
| Mutation | 1 | 1993 | 30052 | 0.010 |
Why?
|
| Binding Sites | 1 | 1998 | 6055 | 0.010 |
Why?
|
| Keratinocytes | 1 | 1993 | 790 | 0.000 |
Why?
|
| DNA | 1 | 1982 | 7212 | 0.000 |
Why?
|
| Liver | 2 | 1984 | 7529 | 0.000 |
Why?
|
| Cell Cycle | 1 | 1996 | 2932 | 0.000 |
Why?
|
| Tissue Distribution | 1 | 1991 | 2265 | 0.000 |
Why?
|
| Genetic Testing | 1 | 2000 | 3537 | 0.000 |
Why?
|
| Decision Making | 1 | 2001 | 3929 | 0.000 |
Why?
|
| Alcohols | 1 | 1967 | 94 | 0.000 |
Why?
|
| Mescaline | 1 | 1966 | 7 | 0.000 |
Why?
|
| Glucose | 1 | 1979 | 4346 | 0.000 |
Why?
|
| Tyramine | 1 | 1966 | 53 | 0.000 |
Why?
|
| Heterozygote | 1 | 1993 | 2787 | 0.000 |
Why?
|
| Dermatitis, Seborrheic | 1 | 1986 | 8 | 0.000 |
Why?
|
| Sequence Analysis, DNA | 1 | 1998 | 4740 | 0.000 |
Why?
|
| Cross-Sectional Studies | 2 | 2003 | 26125 | 0.000 |
Why?
|
| Collagen | 1 | 1994 | 2638 | 0.000 |
Why?
|
| Pregnancy Complications | 1 | 1980 | 2947 | 0.000 |
Why?
|
| Polymorphism, Genetic | 1 | 1996 | 4243 | 0.000 |
Why?
|
| Colonic Neoplasms | 1 | 1998 | 2538 | 0.000 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 1993 | 1496 | 0.000 |
Why?
|
| Prototheca | 1 | 1985 | 3 | 0.000 |
Why?
|
| Transfer Factor | 1 | 1985 | 5 | 0.000 |
Why?
|
| Levamisole | 1 | 1985 | 35 | 0.000 |
Why?
|
| Propionibacterium acnes | 1 | 1985 | 65 | 0.000 |
Why?
|
| Lymphocyte Activation | 1 | 1976 | 5486 | 0.000 |
Why?
|
| Amphotericin B | 1 | 1985 | 142 | 0.000 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 1985 | 11742 | 0.000 |
Why?
|
| Retinal Perforations | 1 | 1986 | 138 | 0.000 |
Why?
|
| Parkinson Disease | 1 | 1978 | 2877 | 0.000 |
Why?
|
| Radiotherapy | 1 | 1971 | 1499 | 0.000 |
Why?
|
| Polymerase Chain Reaction | 1 | 1993 | 6075 | 0.000 |
Why?
|
| Uveal Diseases | 1 | 1983 | 45 | 0.000 |
Why?
|
| Paraffin | 1 | 1983 | 36 | 0.000 |
Why?
|
| Cytokines | 1 | 1998 | 7396 | 0.000 |
Why?
|
| Blister | 1 | 1983 | 86 | 0.000 |
Why?
|
| Cells, Cultured | 1 | 1979 | 18965 | 0.000 |
Why?
|
| Nocardia Infections | 1 | 1983 | 19 | 0.000 |
Why?
|
| Ketoconazole | 1 | 1983 | 97 | 0.000 |
Why?
|
| Histological Techniques | 1 | 1983 | 193 | 0.000 |
Why?
|
| Melanins | 1 | 1985 | 290 | 0.000 |
Why?
|
| Bacterial Vaccines | 1 | 1985 | 401 | 0.000 |
Why?
|
| Debridement | 1 | 1985 | 494 | 0.000 |
Why?
|
| Image Enhancement | 1 | 1993 | 2885 | 0.000 |
Why?
|
| Insulin | 1 | 1977 | 6596 | 0.000 |
Why?
|
| Connective Tissue Diseases | 1 | 1985 | 285 | 0.000 |
Why?
|
| Regional Blood Flow | 1 | 1984 | 1496 | 0.000 |
Why?
|
| T-Lymphocytes | 1 | 1998 | 10194 | 0.000 |
Why?
|
| Pectoralis Muscles | 1 | 1981 | 85 | 0.000 |
Why?
|
| Depression | 1 | 2000 | 8124 | 0.000 |
Why?
|
| Head | 1 | 1986 | 924 | 0.000 |
Why?
|
| Candidiasis | 1 | 1983 | 365 | 0.000 |
Why?
|
| Microscopy, Electron | 1 | 1983 | 2561 | 0.000 |
Why?
|
| Pilot Projects | 1 | 1993 | 8631 | 0.000 |
Why?
|
| Herpes Simplex | 1 | 1983 | 478 | 0.000 |
Why?
|
| Cell Movement | 1 | 1991 | 5203 | 0.000 |
Why?
|
| Dopamine | 1 | 1966 | 1607 | 0.000 |
Why?
|
| Quality of Life | 1 | 2001 | 13367 | 0.000 |
Why?
|
| Thrombosis | 1 | 1993 | 2942 | 0.000 |
Why?
|
| Forearm | 1 | 1981 | 427 | 0.000 |
Why?
|
| Pseudomonas Infections | 1 | 1983 | 622 | 0.000 |
Why?
|
| Bacterial Infections | 1 | 1985 | 1390 | 0.000 |
Why?
|
| Fundus Oculi | 1 | 1977 | 556 | 0.000 |
Why?
|
| Hypertension | 1 | 1974 | 8540 | 0.000 |
Why?
|
| Monocytes | 1 | 1982 | 2570 | 0.000 |
Why?
|
| Leukemia, Lymphoid | 1 | 1971 | 310 | 0.000 |
Why?
|
| Immunity, Innate | 1 | 1983 | 3065 | 0.000 |
Why?
|
| Heart Failure | 1 | 1974 | 11669 | 0.000 |
Why?
|
| Graft Rejection | 1 | 1983 | 4445 | 0.000 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 1985 | 3613 | 0.000 |
Why?
|
| Adipose Tissue | 1 | 1981 | 3312 | 0.000 |
Why?
|
| Kidney Transplantation | 1 | 1983 | 4234 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 1985 | 7407 | 0.000 |
Why?
|
| Inflammation | 1 | 1982 | 10773 | 0.000 |
Why?
|
| Mice | 1 | 1986 | 81525 | 0.000 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1977 | 20570 | 0.000 |
Why?
|